Reactive resistance to anti-angiogenic drugs
نویسندگان
چکیده
منابع مشابه
Reactive resistance to anti-angiogenic drugs
most types of cancers, and particularly in metastatic renal cell carcinoma, with several drugs currently approved for daily clinical practice. However, secondary resistance to this family of drugs is constantly observed, and the mechanisms of resistance remain poorly understood in patients. Recently, we demonstrated that sunitinib, a tyrosine kinase inhibitor, was able to generate resistance to...
متن کاملSales for anti-angiogenic drugs
In 1971, Judah Folkman developed the concept of “anti-angiogenesis” as a potential treatment of cancer due to “the prevention of new vessel sprouts from penetrating into early tumor implant” [1]. Beginning in the 1980’s, the industry exploited the field of anti-angiogenesis for creating new therapeutic molecules in angiogenesisdependent diseases. In 2004, the first anti-angiogenic drug, bevaciz...
متن کاملMechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
Pancreatic cancer remains one of the most lethal and poorly understood human malignancies and will continue to be a major unsolved health problem in the 21(st) century. Despite efforts over the past three decades to improve diagnosis and treatment, the prognosis for patients with pancreatic cancer is extremely poor with or without treatment, and incidence rates are virtually identical to mortal...
متن کاملTargeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Despite the approval of several anti-angiogenic therapies, clinical results remain unsatisfactory, and transient benefits are followed by rapid tumor recurrence. Here, we demonstrate potent anti-angiogenic efficacy of the multi-kinase inhibitors nintedanib and sunitinib in a mouse model of breast cancer. However, after an initial regression, tumors resume growth in the absence of active tumor a...
متن کاملMolecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies
Tumour angiogenesis, described by Folkman in the early seventies, is an essential, complex, and dynamic process necessary for the growth of all solid tumours. Among the angiogenic factors secreted by the tumour cells, the Vascular Endothelial Growth Factor (VEGF) is one of the most important. Most types of human cancer cells express elevated levels of this proangiogenic factor and its receptors...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Aging
سال: 2015
ISSN: 1945-4589
DOI: 10.18632/aging.100748